Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Raynaud's Phenomenon Secondary to Systemic Sclerosis”

28 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 28 results

Testing effectiveness (Phase 2)Study completedNCT03867097
What this trial is testing

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)

Who this might be right for
Raynaud Phenomenon Secondary to Systemic Sclerosis
Civi Biopharma, Inc. 34
Post-approval studies (Phase 4)Study completedNCT00048776
What this trial is testing

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

Who this might be right for
Raynaud's Disease
Otsuka America Pharmaceutical 75
Large-scale testing (Phase 3)UnknownNCT00577304
What this trial is testing

A Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon

Who this might be right for
Raynaud's DiseaseRaynaud's Disease Secondary to SclerodermaRaynaud's Disease Secondary to Other Autoimmune Disease
MediQuest Therapeutics 200
Large-scale testing (Phase 3)Study completedNCT00626665
What this trial is testing

Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma

Who this might be right for
Raynaud Disease
Sanjay Gandhi Postgraduate Institute of Medical Sciences 25
Post-approval studies (Phase 4)Looking for participantsNCT07112183
What this trial is testing

Open Label Treprostinil Raynaud's Study

Who this might be right for
Raynaud's DiseaseRaynaud PhenomenaRaynauds
Brigham and Women's Hospital 30
Large-scale testing (Phase 3)Study completedNCT01117298
What this trial is testing

Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma

Who this might be right for
Raynaud's PhenomenonDigital UlcersScleroderma
Sanjay Gandhi Postgraduate Institute of Medical Sciences 66
Testing effectiveness (Phase 2)Study completedNCT04388176
What this trial is testing

Cold Challenge With C21 in RP

Who this might be right for
Raynaud PhenomenonSystemic Sclerosis
Vicore Pharma AB 20
Large-scale testing (Phase 3)Study completedNCT00266669
What this trial is testing

Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's Phenomenon

Who this might be right for
Raynaud's Disease
MediQuest Therapeutics 200
Testing effectiveness (Phase 2)Ended earlyNCT04915950
What this trial is testing

Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Who this might be right for
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Pfizer 13
Large-scale testing (Phase 3)Not Yet RecruitingNCT07759557
What this trial is testing

Efficacy of A Non-Invasive Botulinum Toxin Microneedle Pad for the Treatment of Secondary Raynaud's Phenomenon

Who this might be right for
Systemic Sclerosis (SSc)Raynaud Disease Secondary to Scleroderma
Khon Kaen University 72
Testing effectiveness (Phase 2)Study completedNCT02228850
What this trial is testing

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Who this might be right for
Raynaud's Phenomenon Secondary to Systemic Sclerosis
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) 35
Testing effectiveness (Phase 2)UnknownNCT02356809
What this trial is testing

Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon

Who this might be right for
Secondary Raynaud's Phenomenon
Artgen Biotech 30
Large-scale testing (Phase 3)Study completedNCT04040322
What this trial is testing

Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)

Who this might be right for
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Civi Biopharma, Inc. 198
Testing effectiveness (Phase 2)Study completedNCT01090492
What this trial is testing

PF-00489791 For The Treatment Of Raynaud's

Who this might be right for
Raynaud's DiseasePeripheral Vascular Disease
Pfizer 243
Testing effectiveness (Phase 2)Study completedNCT02260557
What this trial is testing

Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Who this might be right for
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Actelion 74
Very early researchStudy completedNCT03027674
What this trial is testing

Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud

Who this might be right for
Raynaud Phenomenon Due to TraumaRaynaud DiseaseSystem; Sclerosis+3 more
Pontificia Universidad Catolica de Chile 10
Large-scale testing (Phase 3)Study completedNCT03717961
What this trial is testing

Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis

Who this might be right for
Raynaud Phenomenon Secondary to Systemic Sclerosis
Assistance Publique - Hôpitaux de Paris 91
Testing effectiveness (Phase 2)Study completedNCT04744207
What this trial is testing

Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

Who this might be right for
Systemic Sclerosis
Gesynta Pharma AB 94
Testing effectiveness (Phase 2)Ended earlyNCT01315899
What this trial is testing

Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon

Who this might be right for
Raynaud's Phenomenon
Orion Corporation, Orion Pharma 15
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07748000
What this trial is testing

LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks

Who this might be right for
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Liquidia Technologies, Inc. 75
Next Page